AU2017321625A1 - Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors - Google Patents

Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors Download PDF

Info

Publication number
AU2017321625A1
AU2017321625A1 AU2017321625A AU2017321625A AU2017321625A1 AU 2017321625 A1 AU2017321625 A1 AU 2017321625A1 AU 2017321625 A AU2017321625 A AU 2017321625A AU 2017321625 A AU2017321625 A AU 2017321625A AU 2017321625 A1 AU2017321625 A1 AU 2017321625A1
Authority
AU
Australia
Prior art keywords
icos
scfv
domain
variants
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017321625A
Other languages
English (en)
Inventor
Matthew Bernett
Christine Bonzon
John Desjarlais
Michael Hedvat
Gregory Moore
Umesh S. Muchhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/623,314 external-priority patent/US10787518B2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority claimed from PCT/US2017/049497 external-priority patent/WO2018045110A1/en
Publication of AU2017321625A1 publication Critical patent/AU2017321625A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2017321625A 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors Abandoned AU2017321625A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662381239P 2016-08-30 2016-08-30
US62/381,239 2016-08-30
US201762456033P 2017-02-07 2017-02-07
US62/456,033 2017-02-07
US201762479723P 2017-03-31 2017-03-31
US62/479,723 2017-03-31
US15/623,314 US10787518B2 (en) 2016-06-14 2017-06-14 Bispecific checkpoint inhibitor antibodies
US15/623,314 2017-06-14
PCT/US2017/049497 WO2018045110A1 (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Publications (1)

Publication Number Publication Date
AU2017321625A1 true AU2017321625A1 (en) 2019-04-04

Family

ID=65632988

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017321625A Abandoned AU2017321625A1 (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Country Status (12)

Country Link
EP (1) EP3507306B1 (https=)
JP (2) JP7080219B2 (https=)
KR (2) KR20230130174A (https=)
CN (1) CN110267990B (https=)
AU (1) AU2017321625A1 (https=)
CA (1) CA3035343A1 (https=)
DK (1) DK3507306T3 (https=)
HR (1) HRP20251424T1 (https=)
IL (1) IL265046B2 (https=)
MX (1) MX2023006786A (https=)
SG (1) SG11201901712YA (https=)
ZA (1) ZA201901752B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2915378T3 (es) * 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102170077B1 (ko) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
KR102521276B1 (ko) * 2018-10-31 2023-04-12 바이오아트라, 인코퍼레이티드 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도
AU2021256652A1 (en) * 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
AU2021257570A1 (en) * 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
KR102911451B1 (ko) * 2022-05-24 2026-01-09 건국대학교 글로컬산학협력단 Rps3 결합 단클론 항체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2638072A4 (en) * 2010-11-12 2014-05-07 Univ Rockefeller FUSION PROTEINS FOR HIV THERAPY
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2898100C (en) * 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
CA2902739C (en) * 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (en) * 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
JP6668345B2 (ja) * 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
BR112017011166A2 (pt) * 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
EP3623386B1 (en) * 2015-01-08 2022-04-13 BioNTech SE Agonistic tnf receptor binding agents
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos

Also Published As

Publication number Publication date
EP3507306A1 (en) 2019-07-10
RU2019109147A (ru) 2020-10-05
RU2019109147A3 (https=) 2021-01-22
SG11201901712YA (en) 2019-03-28
IL265046B2 (en) 2025-04-01
DK3507306T3 (da) 2025-10-20
JP2022111148A (ja) 2022-07-29
KR20190044106A (ko) 2019-04-29
JP7080219B2 (ja) 2022-06-03
HRP20251424T1 (hr) 2025-12-19
KR20230130174A (ko) 2023-09-11
MX2023006786A (es) 2023-06-20
EP3507306B1 (en) 2025-10-01
CN110267990B (zh) 2023-11-07
KR102575681B1 (ko) 2023-09-08
JP2019529368A (ja) 2019-10-17
IL265046A (en) 2019-04-30
CA3035343A1 (en) 2018-03-08
CN110267990A (zh) 2019-09-20
ZA201901752B (en) 2020-09-30
IL265046B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US20240026002A1 (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US20250333519A1 (en) Bispecific checkpoint inhibitor antibodies
US10793632B2 (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3029328A1 (en) Heterodimeric antibodies that bind somatostatin receptor 2
EP3507306B1 (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2016365742A1 (en) Heterodimeric antibodies that bind CD3 and PSMA
WO2019195623A2 (en) Heterodimeric antibodies that bind fibroblast activation protein
JP2019529368A5 (https=)
WO2021231969A1 (en) Heterodimeric antibodies that bind msln and cd3
RU2788521C2 (ru) Биспецифические иммуномодулирующие антитела, которые связывают костимуляторные рецепторы и рецепторы контрольных точек
HK40014565A (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
HK40014565B (zh) 结合共刺激性和检查点受体的双特异性免疫调节抗体

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BERNETT, MATTHEW; MOORE, GREGORY; DESJARLAIS, JOHN; HEDVAT, MICHAEL; BONZON, CHRISTINE AND MUCHHAL, UMESH S.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted